HS235, a Novel Activin and GDF Ligand Trap, Is Efficacious in a Model of Obesity-Related HFpEF.
information at:
35Pharma is a clinical-stage biopharmaceutical company focused on developing best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for pulmonary hypertension, obesity and cardiometabolic diseases. 35Pharma leverages its scientific leadership in TGF-beta biology, combined with superior protein engineering, to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta superfamily ligands, while sparing beneficial homeostatic ligands. For more information, please visit www.35pharma.com
Julia Schoelermann,
VP Corporate Development, 35Pharma
info@35pharma.com
Other publications
Subscribe
To receive our press releases, please subscribe to our mailing list
35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics for diseases with high unmet medical need.